Loading...
Market
Which company will have the highest revenue from emergency treatment products in 2024?
2
Resolution / Starting Odds
Purdue Pharma • 25%
ARS Pharmaceuticals • 25%
Pfizer • 25%
Other • 25%
Annual financial reports of the companies
Story
FDA Approves Purdue and ARS Pharmaceuticals' Treatments for Overdoses and Allergies
Aug 9, 2024, 02:16 AM
Purdue Pharma has received approval from the U.S. Food and Drug Administration (FDA) for a new nalmefene hydrochloride auto-injector. This device is designed for the emergency treatment of known or suspected opioid overdoses in adults and pediatric patients aged 12 and older. The approval is part of the FDA's ongoing efforts to broaden access to opioid overdose reversal agents. Additionally, the FDA approved ARS Pharmaceuticals' nasal spray, Neffy, as the first needle-free emergency treatment for potentially fatal allergic reactions, including life-threatening anaphylaxis. Neffy, which contains epinephrine, offers a non-injection alternative to the Epi-Pen, potentially saving lives.
View original story
Similar markets
Eli Lilly • 25%
Novo Nordisk • 25%
Sanofi • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Both equally • 25%
Neither • 25%
Manufacturer A • 25%
Manufacturer B • 25%
Manufacturer C • 25%
Other • 25%
Manufacturer A has largest share • 25%
Manufacturer B has largest share • 25%
Manufacturer C has largest share • 25%
Manufacturer D or others have largest share • 25%
Travere Therapeutics • 25%
Novartis • 25%
Calliditas • 25%
Other • 25%
Ascendis Pharma • 25%
Takeda • 25%
Another existing company • 25%
A new entrant • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Pfizer has the largest market share • 25%
Moderna has the largest market share • 25%
Novavax has the largest market share • 25%
Other companies have the largest market share • 25%
Military • 25%
Civilian Emergency Services • 25%
Both • 25%
Neither • 25%
Jane Street • 25%
Goldman Sachs • 25%
Citadel Securities • 25%
XTX Markets • 25%
Pfizer • 25%
GlaxoSmithKline • 25%
Moderna • 25%
Other • 25%